Oncology Injectables Market

Market Overview:

The global oncology injectables market is expected to exhibit a growth rate (CAGR) of 10.8% during 2023-2028.

Oncology injectables refer to the intravenous drugs that are infused in the body during cancer treatment. These injectables mitigate the growth of cancer-inducing proteins along with killing the malignant cells in the body. Injectable oncology drugs offer enhanced efficacy, increased bioavailability, reduced gastrointestinal irritation, and better compliance. As a result, oncology injectables are widely used for treating various types of cancers.

The rising prevalence of cancer across the globe coupled with the growing awareness towards its early detection is primarily catalysing the demand for oncology injectables. Moreover, several pharmaceutical and biotechnology companies are heavily investing in the development of new anti-cancer intravenous drugs with minimal side effects and target-oriented attack. Across the developed world, the wide presence of advanced medical infrastructure along with the easy accessibility to chemotherapy treatments is further proliferating the market for oncology injectables. Additionally, faster drug approvals from various regulatory bodies, such as the U.S. Food and Drug Administration (FDA), have created a positive impact on the market growth. In emerging economies, factors such as rising healthcare expenditures, increasing penetration of healthcare insurance and improving healthcare infrastructure are propelling the market for oncology injectables. Furthermore, various blockbuster branded oncology injectables are expected to become off-patent in the next few years. This is expected to create huge opportunities for generics and biosimilar manufacturers.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology injectables market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on molecule type, product type, indication, branded/generics and distribution channel.

Breakup by Molecule Type:

• Small Molecule
• Large Molecule
   

Breakup by Product Type:

• Chemotherapy
• Monoclonal Antibodies
• Cytokines
• Peptide Hormones
   

Breakup by Indication:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Liver Cancer
• Esophagus Cancer
• Cervical Cancer
• Others
   

Breakup by Branded/Generics:

• Branded
• Generics
   

Breakup by Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
  • Turkey
  • Saudi Arabia
  • Others
     

Competitive Landscape:

The report has also analysed the competitive landscape of the market along with the profiles of the key players.

Report Coverage:

Key Questions Answered in This Report:

• How has the global oncology injectables market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global oncology injectables market?
• What are the key regional markets?
• What is the breakup of the market based on the molecule type?
• What is the breakup of the market based on the product type?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the branded/generics?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global oncology injectables market and who are the key players?
• What is the degree of competition in the industry?